Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer
Stock Information for Syros Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.